Q-omics provides the consensus-scored RUFY4 profile across patient tissues and cancer cell-line models. RUFY4 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, RUFY4 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, RUFY4 RNA expression shows 14,635 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight SKCM, KIRC, and UVM as cancer lineages where RUFY4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RUFY4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RUFY4 survival associations across molecular data types. RUFY4 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RUFY4 RNA expression–survival associations across cancer types. High RUFY4 expression shows unfavorable associations in KIRC and KIRP, but favorable associations in SKCM, BLCA, HNSC and CESC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for RUFY4 RNA expression.
This table summarizes RUFY4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RUFY4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RUFY4 shows higher tumor expression in KIRC, KIRP, BRCA, CHOL, STAD and LUAD. The KIRC box plot shows higher RUFY4 RNA expression in tumor versus normal tissue (log2 FC = +0.569, t-test p < 0.001).
This table shows molecular features associated with RUFY4 in patient tissues and cancer cell lines. In patient samples, RUFY4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RUFY4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in CNS and BREAST.
